Velik-Salchner C, Tauber H, Rastner V, et al. - Researchers analyzed children undergoing cardiac surgery in this single-institution cohort study to determine clinical results as well as hemostatic impacts of fibrinogen concentrate (FC) in combination with prothrombin complex concentrate (PCC) vs standard treatment with fresh frozen plasma (FFP) in this population. They studied data on 525 children. They used propensity score matching in 210 children in order to attenuate the effect of several baseline features. In this study, good tolerability of FC/PCC was evident and FC/PCC allowed hemostasis to be maintained, even in the very young. Any signal for inferiority of this treatment was not found. FC/PCC was concluded to be a safe option to replace FFP.